Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery. 



Biotechnology

Confo Therapeutics

Confo Therapeutics' headquarters in Elsene, Belgium

Cedric Ververken

Stephen Dowd

Christel Menet

Frank Landolt

Paolo Vicini

Marc Moens

Jan Steyaert

Rob Scott

Radu Aricescu

Peter Kolb

Graeme Milligan

Tim Corn

John Berriman

Edward van Wezel

Jos B. Peeters

Karl Nägler

Filip Goossens

Description

People

Jobs